Company Overview and News

11
Dividend Sensei's Portfolio Update 55: Why I Love Stock Market Corrections

2018-10-16 seekingalpha - 2
Unlike most investors, who fear sharply falling prices, I become most excited when the market runs deep red.
TXN UNIT AQN SHLD IRM BLK NBLX BRX OHI KIM

 
The More It Drops, The More I Buy - Again And Again

2018-10-15 seekingalpha
The REIT market had fully recovered and now sold off once again - another potential opportunity for us to make a quick buck.
PSA.A PSA SRC SRC.WI BRX PSAXZ

39
3 Ways To Protect Your Portfolio From The Next Stock Market Correction

2018-10-15 seekingalpha - 2
Last week saw major market losses that shook many investors and have some worried that another correction is starting.
IRM AMZN BRX KIM

5
4 Reasons I'm Pounding The Table On These 2 Low-Risk, 7+%-Yielding Stocks

2018-10-15 seekingalpha
High-yield value investing often requires taking a contrarian approach. This means sometimes buying high-quality, but deeply out of favor stocks.
HD ROST TJX BLK BRX FRT KIM

 
Ramco: New Leadership Could Elevate This REIT

2018-10-03 seekingalpha
Reader might not recognize the name, but they have not missed much. Ramco has been a pretty mediocre REIT in recent years.
REG XKE RPAI BRX AKR RPT RVI RVI.WI

185
Stocks To Watch: Strap In For Q4

2018-09-29 seekingalpha - 3
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning.
STZ.B SGMS PRTK PLYA BHC 1128 LADR HCA NWN 1928 MTOR WELL AET BGS TSO AMC ARNC PSA MDT CXW OZK MTH CZR CPS SPG FCAU ADS IGT TM LEN CONN WCG FIZZ MPC SJMHY MLCO MOH MZOR YRCW LUV KBH WYNMF HMC 0880 HAS TSLA CRY HLT RPM BYD WYNMY CNC TWX HA SKYW SEM PSA.A CVS LEAF OMF SUI CALM BKS ALGT BCO STAY AAL ADNT WTW STZ NAV MAT UAL BRX ERI PENN ATHN SJMHF DAN JBLU SFIX PIR ANDV ALK CVGW PSAXZ GM DAL PAYX F TRUP CMCSA KPTI COST SCHYF GLPI 506186 PEP GLXYENT ABG THC SCHYY PZZA

 
My Oh My, 4 REIT Buys

2018-09-21 seekingalpha
Over the years, we have developed a large following on Seeking Alpha, as many of our subscribers know that our in-depth research has allowed us to outperform.
BRX JCAP SPG

 
BRX / Brixmor Property Group Inc. FORM 8-K (Current Report)

2018-08-31 sec.gov
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549
BRX

 
BRX / Brixmor Property Group Inc. FORM 8-K (Current Report)

2018-08-31 sec.gov
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549
BRX

 
Red-Hot Economy Boosts 4 High-Yielding Real Estate Investment Trusts

2018-08-17 247wallst
Whether or not you like President Trump, small businesses sure do, and they hire the bulk of the workers in the United States. In fact small business optimism is at the highest level since the Reagan years, and with regulations and taxes getting cut, you can bet that the economy can stay strong.
AHH BRX BDN SPG

 
Brixmor's Management Is Playing The Long Game

2018-08-07 seekingalpha
Nevertheless, portfolio pruning and enhancements, buying back cheap shares, improving operating efficiencies, and aggressively improving liquidity set the company up for long-term outperformance.
BRX

 
Brixmor Property Group Inc. (BRX) CEO James Taylor on Q2 2018 Results - Earnings Call Transcript

2018-08-01 seekingalpha
Brixmor Property Group Inc. (NYSE:BRX) Q2 2018 Earnings Conference Call July 31, 2018 11:00 AM ET
BRX

 
BRX / Brixmor Property Group Inc. 10-Q (Quarterly Report)

2018-07-30 sec.gov
Document UNITED STATES
BRX

 
BRX / Brixmor Property Group Inc. 10-Q (Quarterly Report)

2018-07-30 sec.gov
Document UNITED STATES
BRX

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

Silicon Investor Message Boards

This table lists all message boards related to BRX / Brixmor Property Group Inc. on message board site Silicon Investor.

MBRX under $3 announced big break through for Leukemia MBRX under $3 announced big break through for Leukemia MBRX under $3 announced big break through for Leukemia Metabasis Therapeutics (MBRX) Metabasis Therapeutics (MBRX) Metabasis Therapeutics (MBRX)
SBRX - Stonebridge Resources Explorations Ltd. SBRX - Stonebridge Resources Explorations Ltd. SBRX - Stonebridge Resources Explorations Ltd. ABRX ABLE LABS ABRX ABLE LABS ABRX ABLE LABS
ABRX: ABR Information Services ABRX: ABR Information Services ABRX: ABR Information Services ABR Information Services (ABRX) ABR Information Services (ABRX) ABR Information Services (ABRX)
CUSIP: 11120U105